Fusion, Derived From T(12,16) Malignant Liposarcoma (Humain) Peptide
Reactivité: Humain
Hôte: Synthetic
BP, IHC, WB
-
- Antigène
- Fusion, Derived From T(12,16) Malignant Liposarcoma (Human)
- Origine
- Humain
- Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-FUS antibody (Catalog #: ARP40278_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
- Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Antigène
- Fusion, Derived From T(12,16) Malignant Liposarcoma (Human)
- Sujet
-
FUS binds both single-stranded and double-stranded DNA and promotes ATP-independent annealing of complementary single-stranded DNAs and D-loop formation in superhelical double-stranded DNA. FUS may play a role in maintenance of genomic integrity.
Alias Symbols: FUS-CHOP, FUS1, TLS, ALS6, POMP75, HNRNPP2
Protein Interaction Partner: FUS,GRIN1,GRIN2D,ILF3,POLR2A,PRMT1,PTBP1,RELA,RXRA,SF1,SFPQ,SPI1,SRRM1,SRSF10,SRSF2,SRSF4,THRA,YBX1,ZMYM2,EIF6,ILF3,OTUB1,PRMT1,PTBP2,RELA,RXRA,SARNP,SF1,SPI1,SRRM1,SRSF10,THRA,USF2,YBX1,ZMYM2
Protein Size: 263 - Poids moléculaire
- 29 kDa
- ID gène
- 2521
- NCBI Accession
- NM_001010850, NP_001010850
-
Vous êtes ici:
